Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

The Clinical Significance and Prognostic Value of ALDH1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

Author(s): Dong Li, Yu Cao, Cheng-Wen Luo, Li-ping Zhang and Ying-Bo Zou*

Volume 19, Issue 5, 2024

Published on: 16 October, 2023

Page: [599 - 609] Pages: 11

DOI: 10.2174/0115748928265992230925053308

Price: $65

Abstract

Background: The results of the association between aldehyde dehydrogenase 1 (ALDH1) expression and prognosis of non-small cell lung cancer (NSCLC) are contradictory. We conducted this meta-analysis to investigate the clinical significance and prognostic value of ALDH1 in NSCLC.

Methods: The databases PubMed, Web of Science, EMBASE, the Cochrane Library, Wanfang, and CNKI were systematically queried to identify eligible studies. The retrieval time was from database establishment to August 2023. We evaluated the correlation between ALDH1 expression and clinical features of NSCLC by employing odds ratios (ORs) and 95% confidence intervals (95% CIs). In addition, we used hazard ratios (HRs) and 95% CIs to evaluate the role of ALDH1 expression in the prognosis of NSCLC.

Results: Our study included 21 literatures involving 2721 patients. The expression of ALDH1 in NSCLC was higher than that in normal tissues (OR = 6.04, 95% CI: 1.25-29.27, P = 0.026). The expression of ALDH1 was related to TNM stage (OR = 1.81, 95% CI: 1.06-3.09, P = 0.029), tumor grade (OR = 0.29, 95% CI: 0.17-0.48, P < 0.0001), lymph node metastasis (OR = 2.60, 95% CI: 1.52-4.45, P = 0001) and histological subtype (OR = 0.67, 95% CI: 0.52-0.86, P = 0.002). In patients with NSCLC, we found that the over-expression of ALDH1 was significantly associated with poor overall survival (OS) (HR = 1.44, 95% CI: 1.15-1.81, P = 0.002) and disease-free survival (DFS) (HR = 1.74, 95% CI: 1.45-2.10, P < 0.0001).

Conclusion: The expression of ALDH1 is closely associated with the clinicopathologic characteristics and prognosis of NSCLC. ALDH1 may serve as a valuable clinical assessment tool and prognostic predictor in NSCLC.

« Previous Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Wang Y, Dong L, Zhong H, et al. Extracellular Vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport. Int J Biol Sci 2019; 15(10): 2110-8.
[http://dx.doi.org/10.7150/ijbs.31605] [PMID: 31592232]
[3]
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69(5): 363-85.
[http://dx.doi.org/10.3322/caac.21565] [PMID: 31184787]
[4]
He L, Huang Y, Chen X, et al. Development and validation of an immune-based prognostic risk score for patients with resected non-small cell lung cancer. Front Immunol 2022; 13: 835630.
[http://dx.doi.org/10.3389/fimmu.2022.835630] [PMID: 35401554]
[5]
Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014; 25(8): 1462-74.
[http://dx.doi.org/10.1093/annonc/mdu089] [PMID: 24562446]
[6]
Tsochantaridis I, Roupas A, Mohlin S, Pappa A, Voulgaridou GP. The concept of cancer stem cells: Elaborating on ALDH1B1 as an emerging marker of cancer progression. Life 2023; 13(1): 197.
[http://dx.doi.org/10.3390/life13010197] [PMID: 36676146]
[7]
Chulpanova DS, Rizvanov AA, Solovyeva VV. The role of cancer stem cells and their extracellular vesicles in the modulation of the antitumor immunity. Int J Mol Sci 2022; 24(1): 395.
[http://dx.doi.org/10.3390/ijms24010395] [PMID: 36613838]
[8]
Wang L, Wang L, Yu Y, et al. Aldehyde dehydrogenase 1 in gastric cancer. J Oncol 2022; 2022: 1-5.
[http://dx.doi.org/10.1155/2022/5734549] [PMID: 35310914]
[9]
Vassalli G. Aldehyde dehydrogenases: Not just markers, but functional regulators of stem cells. Stem Cells Int 2019; 2019: 1-15.
[http://dx.doi.org/10.1155/2019/3904645] [PMID: 30733805]
[10]
Han S, Huang T, Wu X, et al. Prognostic value of ALDH1 and Nestin in advanced cancer: A systematic meta-analysis with trial sequential analysis. Ther Adv Med Oncol 2019; 11.
[http://dx.doi.org/10.1177/1758835919830831] [PMID: 30833990]
[11]
Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: A meta-analysis. Oral Oncol 2014; 50(12): 1144-8.
[http://dx.doi.org/10.1016/j.oraloncology.2014.08.018] [PMID: 25264224]
[12]
Zhao W, Zang C, Zhang T, et al. Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: A meta-analysis. OncoTargets Ther 2018; 11: 1821-31.
[http://dx.doi.org/10.2147/OTT.S160207] [PMID: 29662319]
[13]
Chen J, Xia Q, Jiang B, et al. Prognostic value of cancer stem cell marker aldh1 expression in colorectal cancer: A systematic review and meta-analysis. PLoS One 2015; 10(12): e0145164.
[http://dx.doi.org/10.1371/journal.pone.0145164] [PMID: 26682730]
[14]
Zheng Y, Wang L, Yin L, et al. Lung cancer stem cell markers as therapeutic targets: An update on signaling pathways and therapies. Front Oncol 2022; 12: 873994.
[http://dx.doi.org/10.3389/fonc.2022.873994] [PMID: 35719973]
[15]
Merchant AA, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res 2010; 16(12): 3130-40.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2846] [PMID: 20530699]
[16]
Alamgeer M, Ganju V, Szczepny A, et al. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 2013; 68(12): 1095-104.
[http://dx.doi.org/10.1136/thoraxjnl-2012-203021] [PMID: 23878161]
[17]
Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7(3): 330-8.
[http://dx.doi.org/10.1158/1541-7786.MCR-08-0393] [PMID: 19276181]
[18]
Wang Q, Lin C. Expression of ALDH1 and AQP-5 proteins in NSCLC tissues and their relationship with clinical pathological parameters and prognosis of patients. Hebei Medical Journal 2021; 43(4): 548-51.
[http://dx.doi.org/10.3969/j.issn.1002-7386.2021.04.015]
[19]
Yamashita N, So T, Miyata T, et al. Triple-negative expression (ALDH1A1-/CD133-/mutant p53-) cases in lung adenocarcinoma had a good prognosis. Sci Rep 2022; 12(1): 1473.
[http://dx.doi.org/10.1038/s41598-022-05176-0] [PMID: 35087112]
[20]
Zhou L, Yu L, Zhu B, et al. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer. BMC Cancer 2016; 16(1): 876.
[http://dx.doi.org/10.1186/s12885-016-2903-z] [PMID: 27832750]
[21]
Koh YW, Han JH, Haam S, Jung J. ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: A study based on immunohistochemistry and mRNA expression data. J Cancer Res Clin Oncol 2019; 145(6): 1427-36.
[http://dx.doi.org/10.1007/s00432-019-02906-2] [PMID: 30923946]
[22]
Miyata T, Oyama T, Yoshimatsu T, et al. The clinical significance of cancer stem cell markers ALDH1A1 and CD133 in lung adenocarcinoma. Anticancer Res 2017; 37(5): 2541-7.
[http://dx.doi.org/10.21873/anticanres.11597] [PMID: 28476825]
[23]
Xue J, Zhao Y, Zou Q, Liang F, Lin F. The clinical and prognostic impact of aldehyde dehydrogenase 1 in non-small cell lung cancer: A meta-analysis. Transl Cancer Res 2020; 9(3): 1914-25.
[http://dx.doi.org/10.21037/tcr.2020.02.09] [PMID: 35117538]
[24]
Wei D, Peng JJ, Gao H, Zhang T, Tan Y, Hu YH. ALDH1 expression and the prognosis of lung cancer: A systematic review and meta-analysis. Heart Lung Circ 2015; 24(8): 780-8.
[http://dx.doi.org/10.1016/j.hlc.2015.03.021] [PMID: 25921687]
[25]
Huo W, Du M, Pan X, Zhu X, Li Z. Prognostic value of ALDH1 expression in lung cancer: A meta-analysis. Int J Clin Exp Med 2015; 8(2): 2045-51.
[PMID: 25932135]
[26]
Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17(24): 2815-34.
[http://dx.doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8] [PMID: 9921604]
[27]
Chi T, Wu S. Expression of the aldehyde dehydrogenase 1 and KAI1 in non-small cell lung cancer and its clinicopathological significance. J Bengbu Med Coll 2016; 41(9): 1138-41.
[http://dx.doi.org/10.13898/j.cnki.issn.1000-2200.2016.09.006]
[28]
Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA, Karoubi G. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur J Cardiothorac Surg 2012; 41(6): e173. (e181)
[http://dx.doi.org/10.1093/ejcts/ezs170]
[29]
Gao F, Zhou B, Xu JC, et al. The role of LGR5 and ALDH1A1 in non-small cell lung cancer: Cancer progression and prognosis. Biochem Biophys Res Commun 2015; 462(2): 91-8.
[http://dx.doi.org/10.1016/j.bbrc.2015.04.029] [PMID: 25881507]
[30]
Hu K. The Expression and significance of ALDH1 and ABCG2 in Non-small-cell lung cancer. Bengbu Medical College 2013.
[31]
Huang H, Zhang J, Qiu X. Expression and significance of acetaldehyde dehydrogenase 1 in non-small cell lung cancer. Shandong Yiyao 2011; 51(49): 41-2.
[http://dx.doi.org/10.3969/j.issn.1002-266X.2011.49.026]
[32]
Li Q. Expressin and cilnical significance of Setm Cell Marker CD133, CD34 and ALDHA1 in Lung Cancer. Qingdao University 2012.
[33]
Li X, Wan L, Geng J, Wu CL, Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol 2012; 7(8): 1235-45.
[http://dx.doi.org/10.1097/JTO.0b013e318257cc6d]
[34]
Okudela K, Woo T, Mitsui H, et al. Downregulation of ALDH1A1 expression in non-small cell lung carcinomas--its clinicopathologic and biological significance. Int J Clin Exp Pathol 2013; 6(1): 1-12.
[PMID: 23236537]
[35]
Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int 2012; 62(12): 792-801.
[http://dx.doi.org/10.1111/pin.12019] [PMID: 23252868]
[36]
Park E, Park SY, Sun PL, et al. Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma. Oncotarget 2106; 7(27): 42502-12.
[http://dx.doi.org/10.18632/oncotarget.9894] [PMID: 27285762]
[37]
Shien K, Toyooka S, Ichimura K, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 2012; 77(1): 162-7.
[http://dx.doi.org/10.1016/j.lungcan.2012.02.006] [PMID: 22387005]
[38]
Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010; 70(23): 9937-48.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-0881] [PMID: 21118965]
[39]
Zenke Y, Ishii G, Ohe Y, et al. Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: Identification of prognostic microenvironmental factors after chemoradiation. Pathol Int 2013; 63(12): 599-606.
[http://dx.doi.org/10.1111/pin.12122] [PMID: 24422956]
[40]
Zhuo Y, Liang D. Study on ALDH1 as the functional marker of lung cancer stem cells. Modern Journal of Integrated Traditional Chinese and Western Medicine 2015; 24(33): 3652-4.
[http://dx.doi.org/10.3969/j.issn.1008-8849.2015.33.001]
[41]
Blomqvist M, Koskinen I, Löyttyniemi E, Mirtti T, Boström PJ, Taimen P. Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Sci Rep 2021; 11(1): 13684.
[http://dx.doi.org/10.1038/s41598-021-93245-1] [PMID: 34211078]
[42]
Ruscito I, Darb-Esfahani S, Kulbe H, et al. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecol Oncol 2018; 150(1): 151-7.
[http://dx.doi.org/10.1016/j.ygyno.2018.05.006] [PMID: 29753392]
[43]
Wei Y, Li Y, Chen Y, et al. ALDH1: A potential therapeutic target for cancer stem cells in solid tumors. Front Oncol 2022; 12: 1026278.
[http://dx.doi.org/10.3389/fonc.2022.1026278] [PMID: 36387165]
[44]
Lei HM, Zhang KR, Wang CH, et al. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. Theranostics 2019; 9(24): 7122-39.
[http://dx.doi.org/10.7150/thno.35729] [PMID: 31695757]
[45]
Li Y, Wang B, Gui S, Ji J. Multiple copies in T-Cell Malignancy 1 (MCT-1) promotes the stemness of non-small cell lung cancer cells via activating interleukin-6 (IL-6) signaling through suppressing MiR-34a expression. Med Sci Monit 2019; 25: 10198-204.
[http://dx.doi.org/10.12659/MSM.919690] [PMID: 31891569]
[46]
Jin L, Wu Z, Wang Y, Zhao X. Cryptotanshinone attenuates the stemness of non-small cell lung cancer cells via promoting TAZ translocation from nuclear to cytoplasm. Chin Med 2020; 15(1): 66.
[http://dx.doi.org/10.1186/s13020-020-00348-4] [PMID: 32612672]
[47]
Liu M, Wu H, Xu C. Targeting cancer stem cell pathways for lung cancer therapy. Curr Opin Oncol 2023; 35(1): 78-85.
[http://dx.doi.org/10.1097/CCO.0000000000000912] [PMID: 36475460]
[48]
MacDonagh L, Santiago RM, Gray SG, et al. Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. Transl Oncol 2021; 14(4): 101025.
[http://dx.doi.org/10.1016/j.tranon.2021.101025] [PMID: 33550205]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy